focus -WSS

focus

author：comprehensive 2025-09-30 23:38:43 - browse：65488

Illustration of a red human heart with an EKG line in the middle. -- health coverage from STAT — Adobe

Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of heart complications in a major trial, the company now has results from a different study showing the treatment can also benefit people with a common type of heart failure.

The results, published Friday in the New England Journal of Medicine, found that among people with obesity and heart failure with preserved ejection fraction, or HFpEF, those taking Wegovy experienced greater improvements in symptoms and physical function compared with those on placebo. The improvements were greater than what’s been seen in trials of some other HFpEF treatments.

Novo previously shared topline results in investor calls, but the new study contains the full findings, which are also being presented at the European Society of Cardiology conference this week.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： How a Boston hospital is priming medical residents to use GPT

WSS

In rare move, senator releases unverified FBI source report alleging Biden bribe

Delta passengers in Vegas fall sick while waiting on flight in triple

Hormonal contraceptives don’t actually treat endometriosis

5 dead in mass shooting on Caribbean island of St. Vincent: Police

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Quicker fix for pulse oximeters urged during FDA public meeting

Wikipedia

focus

hotspot

23andMe had bad news about my health. I wish a person had delivered it

Novo Nordisk to expand supply of Wegovy for U.S. patients

Trump demands the U.S. pay no more for drugs than other countries … again

Cognito secures funding to test medical device for Alzheimer's

Medical records are filled with copy

Covid misinformation case heads to Supreme Court

BioMarin wins approval for gene therapy to treat hemophilia A

Telehealth startups are trying to fill the menopause care vacuum

Trump demands the U.S. pay no more for drugs than other countries … again

Caribou posts encouraging results on off

leisure time

How a Boston hospital is priming medical residents to use GPT

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Dementia risk linked to living in disadvantaged areas: Study

Vertigo drug brings hope for rare neuron disorder, Niemann

Scientists grapple with ethics of stem cell research

leisure time

Wikipedia

hotspot

Wikipedia